Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > AEZS's test vs. the clonidine and an arginine test
View:
Post by prophetoffactz on Jun 23, 2024 1:11pm

AEZS's test vs. the clonidine and an arginine test

AEZS's pediatric trial: clinicaltrials.gov, "The macimorelin test will be compared to a clonidine and an arginine test."

How does AEZS's test compare to those tests? I don't know the GH cutoff chosen in AEZS's pediatric trial. Below 
5.1 ng/mL was assumed and was a superior cutoff in previous macimorelin results. You can see how an oral test would be superior for children. 

Perplexity Ai: 

Based on the search results, macimorelin does appear to have several advantages over clonidine and arginine tests for diagnosing growth hormone deficiency (GHD), which could make it a preferred option. Here are the key points:

Advantages of Macimorelin

  1. Higher Sensitivity:
    • Macimorelin: 92-93% sensitivity at a GH cutoff of 5.1 ng/mL.
    • Clonidine: Approximately 85% sensitivity.
    • Arginine: Approximately 78% sensitivity.
  2. Reproducibility:
    • Macimorelin: 94% reproducibility.
    • ITT: Varies, but generally less consistent, especially in different patient populations.
  3. Safety and Tolerability:
    • Macimorelin is well-tolerated with fewer side effects, primarily mild dysgeusia (unpleasant taste).
    • Clonidine can cause hypotension and drowsiness, which may prolong fasting and induce hypoglycemia.
    • Arginine can cause nausea, vomiting, and other side effects.
  4. Convenience:
    • Macimorelin is orally administered and has a shorter test duration (90 minutes).
    • Clonidine and arginine tests require intravenous administration and can be more time-consuming.

Potential for Becoming the Go-To Test

Given these advantages, macimorelin is likely to become a preferred diagnostic test for GHD. Its higher sensitivity and reproducibility, combined with ease of administration and better safety profile, make it a strong candidate for widespread use.

Impact on Misdiagnosis

Regarding whether macimorelin leads to fewer people being treated for GHD who shouldn't be:
  • Specificity: Macimorelin has a high specificity of 96-97% at the 5.1 ng/mL cutoff. This means it has a low rate of false positives, which reduces the likelihood of misdiagnosing individuals without GHD as having the condition.
  • Comparison to Other Tests: The specificity of macimorelin is comparable to or better than other tests, suggesting it is effective in correctly identifying those without the condition.

Conclusion

Macimorelin's superior sensitivity, reproducibility, and safety profile, along with its convenience, make it a strong candidate to become the go-to test for diagnosing GHD. Its high specificity also suggests it is less likely to result in unnecessary treatment for individuals who do not have GHD. However, the final adoption will depend on further validation, especially in pediatric populations, and considerations of cost and availability.
Comment by prophetoffactz on Jun 23, 2024 2:19pm
Perplexity Ai: The Macimorelin stimulation test is an orally administered test that takes approximately 90 minutes to complete, with blood samples taken at intervals of 30, 45, 60, and 90 minutes after administration.In contrast, the clonidine and arginine tests are more time-consuming and require intravenous administration: Clonidine Test: This test typically involves administering ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities